-
2023-509767-25-00
1
2024-11-07
Advanced PRAME Positive Cancers
-
2023-509912-27-00
5
2024-11-07
Metabolic Dysfunction-Associated Steatotic Liver Disease(MASH) / Nonal
-
2024-516242-19-00
5
2024-11-05
lupus nephritis
-
2023-504620-26-00
4
2024-11-04
Triple negative breast cancer
-
2024-514240-93-00
10
2024-10-31
Idiopathic nephrotic syndrome (INS)
-
2024-514899-41-00
4
2024-10-31
Breast cancer
-
2023-505334-10-01
7
2024-10-30
Unresectable, Locally Advanced, or Metastatic Solid Tumors
-
2023-510395-31-00
5
2024-10-30
Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Compensat
-
2024-511453-22-00
1
2024-10-28
Participants with Advanced Solid Malignancies
-
2024-514241-10-00
4
2024-10-22
Kaposi's sarcoma
-
2024-515300-39-00
4
2024-10-18
METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA OF G
-
2024-516782-36-00
4
2024-10-15
metastatic or recurrent endometrial or ovarian carcinosarcoma
-
2024-514610-13-00
5
2024-10-04
patients suffering from acute myocarditis confirmed on Cardiac magneti
-
2023-510203-21-00
7
2024-09-24
locally advanced or metastatic non-small cell lung cancer (NSCLC) resi
-
2024-511070-68-01
5
2024-09-24
Ampullary adenocarcinoma
-
2024-511238-11-00
1
2024-09-20
Ovarian cancer, endometrial cancer, cervical cancer, non-small cell lu
-
2023-504513-77-00
4
2024-09-16
Adult patients older than 18 years. Patients admitted to the participa
-
2024-515118-42-00
11
2024-09-10
Colorectal cancer
-
2022-502408-57-00
5
2024-09-04
Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients hav
-
2024-515774-27-00
6
2024-09-03
Atrial Fibrillation, atrial appendage, anticoagulants, stroke, platele
-
2023-506216-40-00
5
2024-08-14
CytoMegaloVirus infections
-
2023-503429-20-00
8
2024-07-31
Light Chain Amyloidosis
-
2023-508260-30-01
5
2024-07-30
Patients with poor prognostic OVARian cancers based on the tumor prima
-
2023-507684-19-00
5
2024-07-24
FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer